Author:
Xia Yin Yin,Hu Dai Yu,Liu Fei Ying,Wang Xiao Meng,Yuan Yan Li,Tu De Hua,Chen Yi Xin,Zhou Lin,Zhu Li Zhen,Gao Wei Wei,Wang Hong Yuan,Chen Da Fang,Yang Li,He Ping Ping,Li Xiao Ting,He Ying Jian,Sun Feng,Zhan Si Yan
Abstract
Abstract
Background
More than 1 million tuberculosis (TB) patients are receiving the standard anti-TB treatment provided by China National Tuberculosis Prevention and Control Scheme (CNTS) in China every year. Adverse reactions (ADRs) induced by anti-TB drugs could both do harm to patients and lead to anti-TB treatment failure. The ADACS aimed to explore ADRs' incidences, prognoses, economical and public health impacts for TB patients and TB control, and build a DNA bank of TB patients.
Methods/Design
Multiple study designs were adopted. Firstly, a prospective cohort with 4488 sputum smears positive pulmonary tuberculosis patients was established. Patients were followed up for 6-9 months in 52 counties of four regions. Those suspected ADRs should be checked and confirmed by Chinese State Food and Drug Administration (SFDA). Secondly, if the suspected ADR was anti-TB drug induced liver injury (ATLI), a nested case-control study would be performed which comprised choosing a matched control and doing a plus questionnaire inquiry. Thirdly, health economical data of ADRs would be collected to analyze financial burdens brought by ADRs and cost-effectiveness of ADRs' treatments. Fourthly, a drop of intravenous blood for each patient was taken and saved in FTA card for DNA banking and genotyping. Finally, the demographic, clinical, environmental, administrative and genetic data would be merged for the comprehensive analysis.
Discussion
ADACS will give an overview of anti-TB drugs induced ADRs' incidences, risk factors, treatments, prognoses, and clinical, economical and public health impacts for TB patients applying CNTS regimen in China, and provide suggestions for individualized health care and TB control policy.
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference38 articles.
1. WHO: Global tuberculosis control: epidemiology, strategy, financing. 2009, P7-46. WHO document WHO/CDS/TB;
2. WHO: An expanded DOTS framework for effective tuberculosis control.Stop TB Communicable Diseases. 2002, 1-20. WHO document WHO/CDS/TB;
3. Xianyi C, Fengzeng Z, Hongjin D, Liya W, Lixia W, Xin D, Chin DP: The DOTS strategy in China: results and lessons after 10 years. Bull World Health Organ. 2002, 80 (6): 430-436.
4. Awofeso N: Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. Bull World Health Organ. 2008, 86 (3): B-D.
5. Berg J, Blumberg EJ, Sipan CL, Friedman LS, Kelley NJ, Vera AY, Hofstetter CR, Hovell MF: Somatic complaints and isoniazid (INH) side effects in Latino adolescents with latent tuberculosis infection (LTBI). Patient Educ Couns. 2004, 52 (1): 31-39. 10.1016/S0738-3991(02)00268-9.